Nakom (Carbidopa, Levodopa)

Levodopa serves as a precursor that crosses the blood‑brain barrier and is converted into dopamine, replenishing the neurotransmitter that is deficient in Parkinsonian disorders. Carbidopa blocks peripheral decarboxylation of levodopa, allowing more of the drug to reach the brain and reducing nausea and other peripheral side effects.

The appropriate dose of Nakom is individualized by the prescribing clinician based on the patient’s disease severity, response to therapy, age, and renal function. Dosage adjustments are made during treatment to balance symptom control with tolerability, and no fixed regimen is provided here.

The pregnancy category for carbidopa/levodopa is listed as unknown, and there is limited clinical data on its use in pregnant or lactating women. Consequently, the drug should only be used if the potential benefit justifies the potential risk, and a healthcare professional should be consulted before use.

To request Nakom, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nakom provides direct dopamine replacement, whereas dopamine agonists stimulate dopamine receptors without increasing dopamine levels. MAO‑B inhibitors prevent dopamine breakdown, offering a different mechanism. Carbidopa/levodopa generally provides the most robust symptom control but may be associated with motor complications such as dyskinesia, which are less common with some alternatives.

Nakom tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

Nakom is taken orally with a glass of water. It may be taken with or without food, although a high‑protein meal can interfere with levodopa absorption, so spacing the dose from protein‑rich meals is often recommended. The tablet should be swallowed whole and not crushed or chewed unless specifically instructed by a clinician.

Serious adverse reactions include dyskinesia (involuntary movements), neuroleptic malignant syndrome, severe hypotension, cardiac arrhythmias, hallucinations, and profound depression or suicidal thoughts. Patients should be monitored closely for these events, and any sudden changes in mood or motor function should be reported to a healthcare provider immediately.

Nakom should be avoided in individuals with known hypersensitivity to carbidopa, levodopa, or any excipients. It is also contraindicated in patients with narrow‑angle glaucoma, malignant melanoma, or those taking non‑selective MAO inhibitors. Caution is advised for patients with severe cardiovascular disease, hepatic impairment, or a history of psychosis.